• J. Thorac. Cardiovasc. Surg. · Dec 1988

    Seven years' experience with the Pierce-Donachy ventricular assist device.

    • D G Pennington, K R Kanter, L R McBride, G C Kaiser, H B Barner, L W Miller, K S Naunheim, A C Fiore, and V Willman.
    • Department of Surgery, St. Louis University Hospital, Mo.
    • J. Thorac. Cardiovasc. Surg. 1988 Dec 1;96(6):901-11.

    AbstractOf currently available methods for mechanical circulatory support, the Pierce-Donachy external pneumatic ventricular assist device has proved to be one of the most versatile and effective. Since 1981, 48 patients, aged 15 to 71 years (mean 43.0), with profound cardiogenic shock refractory to conventional therapy with drugs and intra-aortic balloon support, were supported with the Pierce-Donachy ventricular assist device. There were four patient groups. The largest group consisted of 30 patients with cardiogenic shock after cardiac operations. Nine required left ventricular support, six needed right ventricular support plus an intraaortic balloon pump, and 15 had biventricular support. Duration of support ranged from 3 hours to 22 days (mean 3.6 days). Eight of the first 11 patients died in the operating room of bleeding and/or biventricular failure. However, 16 patients, (53%) had improved cardiac function, 15 (50%) were weaned, and 11 (36%) were discharged. Of the last 19 patients, 47% survived. Frequent factors in nonsurvivors were myocardial infarction (75%) and renal failure (90%). Common complications in all patients were bleeding (52%) and infection (27%). The second group consisted of 11 patients with end-stage cardiomyopathy or acute myocardial infarction in whom the Pierce-Donachy ventricular assist device was used as a bridge to transplantation (left ventricular support, four patients; biventricular support, seven patients). Renal failure, infection, or coagulopathy that precluded transplantation developed in five patients. Five patients were supported for 8 hours to 75 days (mean 20.7 days) before undergoing successful transplantation, with one late death (six months) from rejection owing to noncompliance. One has subsequently undergone successful transplantation after 84 days of support. The third group consisted of four patients, aged 40 to 56 years (means 47.2), who had refractory cardiogenic shock after cardiac transplantation caused by pulmonary hypertension (two patients), hyperacute rejection (one patient), or graft failure (one patient). Despite biventricular support in all four (biventricular assist devices, two patients; right ventricular assist device plus intraaortic balloon pump, two patients), all died of infection and/or renal failure after 12 hours to 6 days (mean 3.4 days) of support. The final group consisted of three patients, aged 36 to 51 years (mean 45), with cardiogenic shock caused by acute myocardial infarction. One patient was supported with biventricular assist devices (3.5 days) and two patients were supported with a left ventricular assist device (8.5 and 15 days).(ABSTRACT TRUNCATED AT 400 WORDS)

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.